Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - September 2013


SMi - Cancer Vaccines

18 Sep 2013 - 19 Sep 2013 - London, UK



Bookmark and Share


SMi proudly presents the 2nd annual conference on Cancer Vaccines taking place on 18th and 19th September, London. This year’s event aims to focus on innovation and novel strategies within the field, the regulatory environment, and the future direction of cancer vaccines; as well as offering current preclinical and clinical outlook, data, and case studies.

As cancer is still one of the greatest causes of human mortality it is a very attractive target for vaccination. Despite a dramatic increase in research within cancer vaccines in the last decade, there is still a need for more effective therapies to maximise cancer survival rates. Novel strategies for target selection, vaccine design, immunostimulatory therapies, and other biologics are constantly being developed and improved.

Cancer Vaccine 2013 will examine not only current clinical data but also the new innovations within the field. This informative event will draw from expert opinions, groundbreaking data, and regulatory factors to look to the future and assess where the field is advancing. This really is a unique event not to be missed.

Benefits of Attending:

Explore innovative and novel strategies, approaches, and vaccines within the field.

Discover future trends, the direction of the field, and combination strategies in both preclinical and clinical situations.

Evaluate the regulatory environment and the subsequent impact on cancer vaccine development.

Consider current trial data, clinical developments, and successful therapeutic vaccines

Learn from successes, failures, and challenges from experts in the field, and apply to optimise vaccine development

Speakers include:

Alex Kudrin, Medical Assessor, Biologicals Licensing, MHRA

Kevin Pollock, Senior Epidemiologist, NHS National Services Scotland

Martin Glennie, Professor of Immunochemistry, University Of Southampton

Pierre van der Bruggen, Group Leader, Ludwig Institute for Cancer Research

Rose-Ann Padua, Research Director, INSERM

Sonia Quaratino, Senior Medical Director and Immunology Advisor, Merck Serono

REGISTER ONLINE AT www.smi-online.co.uk/goto/2013cancervaccinesevent47.asp

For further information, contact Fateja Begum on Tel: +44 (0)20 7827 6184 or email fbegum@smi-online.co.uk



Further information
Scientific News
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!